I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Medpage Today on MSN12h
Chicken Broth Recall; Medicaid at Risk; Princess Kate Thanks Medical StaffPrincess of Wales Kate Middleton made a personal visit to thank the medical staff and speak with patients at the Royal ...
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...
The FDA is set to consider approval of an alternative to opioids developed by Vertex Pharmaceuticals, The Washington Post reported Jan. 13.
Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...
“Suzetrigine has again demonstrated its potential to fill an important unmet need in the treatment of pain. Today's LSR results are consistent with previous studies of this pain signal inhibitor in ...
BOSTON, December 19, 2024--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly ...
Hosted on MSN1d
New Painkiller May Be 'Landmark Development'The FDA is expected to grant approval to a new pain medication with big potential—mainly because it's a non-opioid and is ...
“Suzetrigine has again demonstrated its potential to fill an important unmet need in the treatment of pain. Today's LSR results are consistent with previous studies of this pain signal inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback